Overview

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.
Phase:
Phase 3
Details
Lead Sponsor:
Mylan Inc.
Collaborator:
Mylan GmbH
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc